14. Clinical benefit table: Fermathron. Continuous outcome measures.

Study	Time	Treatment	Outcome	N of Pts	Baseline Mean	End of Study Mean	Absolute Benefit	Relative Difference
McDonald 2000	1‐4 wk	E: Fermathron	Lequesne Index (0‐24)	114	11.21	7.92	0.37 (W)	3.3% (W)
		C: Hyalart		119	11.12	7.46
McDonald 2000	5‐13 wk	E: Fermathron	Lequesne Index (0‐24)	114	11.21	6.91	0.46 (W)	4.1% (W)
		C: Hyalart		119	11.12	6.36
McDonald 2000	1‐4 wk	E: Fermathron	Pain (0‐100 mm VAS)	114	56.2	31.3	3.3 (W)	5.8% (W)
		C: Hyalart		119	57.2	29.0
McDonald 2000	5‐13 wk	E: Fermathron	Pain (0‐100 mm VAS)	114	56.2	25.4	1.8 (W)	3.1% (W)
		C: Hyalart		119	57.2	24.6